MYOV News and Press, Myovant Sciences Ltd. From 08/09/22

SVB Securities has upgraded Myovant Securities ( NYSE: MYOV ) to outperform from market perform due to the recent approval of Myfembree for pain associated with endometriosis and tailwinds from an existing approval in in uterine fibroids. The firm also upgraded the pri...

Bonso Electronics International ( BNSO ) +158% . MAGIC EMPIRE GLOBAL ( MEGL ) +101% . Karuna Therapeutics ( KRTX ) +50% as schizophrenia trial meets key goal. Bed Bath & Beyond  ( BBBY ) +38% . Iveda Solutions ( IVDA ) +...

Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with endometriosis, and a loss of mean bone mineral density of less than 1% from baseline through one year of treatment Myovant and Pfizer will conti...

Image source: The Motley Fool. Myovant Sciences Ltd. (NYSE: MYOV) Q1 2022 Earnings Call Jul 27, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Myovant Sciences Ltd. (MYOV) Q1 2022 Earnings Call Transcript

Myovant Sciences Ltd. (MYOV) Q1 2022 Results Conference Call July 27, 2022 05:00 PM ET Company Participants Uneek Mehra - Chief Financial & Business Officer Dave Marek - Chief Executive Officer Lauren Merendino - Chief Commercial Officer Dr. Juan Camilo A...

Myovant Sciences ( NYSE: MYOV ) stock has gained 6.1% to $12.98 after hours on Wednesday, as the pharmaceutical company reported a huge jump in Q1 revenue and a narrower quarterly loss per share. MYOV said its Q1 revenue nearly tripled Y/Y to $116.49M, helped by a ...

First fiscal quarter 2022 total revenue of $116.5 million, including net product revenue of $41.4 million Net product revenue from U.S. sales of ORGOVYX ® of $36.0 million in first fiscal quarter 2022, with sequential quarterly demand volume growth of 26% an...

I last updated on Myovant in March, giving the stock a Hold recommendation. The company markets and sells ORGOVYX indicated for prostate cancer and MTFEMBREE, indicated for menstrual bleeding, both derived from drug relugolix. Both indications have been advertised as potential blo...

Myovant has performed well since the regulatory setback in April. The PDUFA date for the sNDA for Myfembree has been extended by three months and Orgovyx was approved in Europe. Myovant has also made commercial progress with Orgovyx delivering strong sequential growth. The PDU...

BASEL, Switzerland, July 13, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its first fiscal quarter, ended June 30, 2022. The webcast and conference call will be ...